We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · January 25, 2022

Pembrolizumab Outperforms TKIs in Patients With High-Risk Renal Cell Carcinoma After Nephrectomy

European Urology Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

European Urology Oncology
Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy
Eur Urol Oncol 2022 Jan 03;[EPub Ahead of Print], E Laukhtina, F Quhal, K Mori, R Sari Motlagh, P Rajwa, T Yanagisawa, H Mostafaei, F König, A Aydh, B Pradere, D Enikeev, PI Karakiewicz, M Schmidinger, SF Shariat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading